Why the study?
Does self-expandable TAVI reduce adverse outcomes compared to balloon-expandable TAVI in patients with severe symptomatic aortic stenosis?
Does self-expandable TAVI reduce adverse outcomes compared to balloon-expandable TAVI in patients with severe symptomatic aortic stenosis?
In a real-world retrospective analysis, self-expandable TAVI was associated with higher 30-day rates of moderate or greater paravalvular regurgitation, stroke, and pacemaker insertion compared to balloon-expandable TAVI.
SEV was associated with higher 30-day PAR, stroke, and pacemaker rates than BEV; leaves open optimal valve selection pending randomized data.
This real-world retrospective analysis demonstrates higher rates of ≥ moderate PAR, stroke and pacemaker insertion with SEV compared to BEV at 30 d post-TAVI for severe symptomatic AS.
No takes yet. Share an insight, caveat, or question.
Tham et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: